Posted by Michael Wonder on 06 Dec 2024
Johnson & Johnson seeks US FDA approval for first paediatric indications for Tremfya (guselkumab)
2 December 2024 - Applications filed for Tremfya to treat children with moderate to severe plaque psoriasis and active juvenile psoriatic arthritis.
Johnson & Johnson today announced the submission of two supplemental biologics license applications to the US FDA seeking approval of Tremfya (guselkumab) for the treatment of children 6 years and older with moderate-to-severe plaque psoriasis and children 5 years of age and older with active juvenile psoriatic arthritis.
